Notícias e Atividades da Storm Therapeutics

Fusão, aquisição e financiamento envolvendo Storm Therapeutics.

• Storm Therapeutics acaba de anunciar uma arrecadação de fundos de 56 milhões de dólares. (publicado em 16 de abril de 2026).

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da Storm Therapeutics

• Jerry McMahon, Chief Executive Officer & President
• Paul Workman, Director
• Tony Kouzarides, Director

Recentes movimentos de executivos em Storm Therapeutics

• Atif Abbas, Chief Medical Officer, deixou a Companhia  (Notícia publicada em 8 de abril de 2026).

Criar um alerta
para seguir os movimentos de executivos da Storm Therapeutics.

Storm Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Storm Therapeutics

• STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM The
• STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• Events | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024 | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics
• View more press releases Close

Redes sociais sobre Storm Therapeutics

• Storm Therapeutics na Wikipedia, Google News e Yahoo Finance
• Storm Therapeutics na LinkedIn, X (Twitter) e YouTube